Cargando…

REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study

BACKGROUND: The efficacy of mepolizumab is well documented in severe eosinophilic asthma (SEA), although the stringent selection criteria adopted by SEA clinical trials limits the generalizability of results. OBJECTIVE: Our study evaluated the effectiveness and safety of mepolizumab in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Domingo Ribas, Christian, Carrillo Díaz, Teresa, Blanco Aparicio, Marina, Martínez Moragón, Eva, Banas Conejero, David, Sánchez Herrero, M. Guadalupe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550660/ https://www.ncbi.nlm.nih.gov/pubmed/34586602 http://dx.doi.org/10.1007/s40265-021-01597-9

Ejemplares similares

Correction to: REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study
por: Domingo Ribas , Christian, et al.
Publicado: (2021)

Potential impact of mepolizumab in stepping down anti-osteporotic treatment in corticosteroid-dependent asthma
por: Domingo, Christian, et al.
Publicado: (2023)

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
por: Pavord, Ian, et al.
Publicado: (2023)

The worls of physics : readings in the nature history, and challenge of physics
Publicado: (1960)

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
por: Moran, Angela M., et al.
Publicado: (2020)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

The state of the Worl-Wide Web (Abstract only)
por: Cailliau, Robert
Publicado: (1995)

Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
por: Howarth, Peter, et al.
Publicado: (2020)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)

Guaranteeing uptime at worl's largest particle physics lab
por: Brodkin, Jon
Publicado: (2007)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
por: Haldar, Pranabashis
Publicado: (2017)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
por: Numata, Takanori, et al.
Publicado: (2019)

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
por: Prazma, Charlene M, et al.
Publicado: (2021)

Differential effects of short- and long-term treatment with mepolizumab on eosinophil kinetics in blood and sputum in eosinophilic asthma
por: Hassani, Marwan, et al.
Publicado: (2021)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment
por: Magnan, A., et al.
Publicado: (2016)

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
por: Varricchi, Gilda, et al.
Publicado: (2016)

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
por: Matsuno, Osamu, et al.
Publicado: (2019)

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
por: Emma, Rosalia, et al.
Publicado: (2018)

Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice
por: Montero-Pérez, Olalla, et al.
Publicado: (2019)

Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma
por: Wardlaw, Andrew, et al.
Publicado: (2020)

Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use
por: Albers, Frank C., et al.
Publicado: (2019)

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma
por: Gupta, Atul, et al.
Publicado: (2019)

Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma
por: Kobayashi, Konomi, et al.
Publicado: (2021)

Eosinophilic cellulitis (Wells syndrome) successfully treated with mepolizumab
por: Herout, Sandra, et al.
Publicado: (2018)

Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis
por: Pradhan, Ravi Ranjan, et al.
Publicado: (2019)

Precision medicine in COPD: review of mepolizumab for eosinophilic COPD
por: Long, Gabriella, et al.
Publicado: (2018)

Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
por: Mkorombindo, Takudzwa, et al.
Publicado: (2019)

Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty
por: Otoshi, Ryota, et al.
Publicado: (2019)

Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO
por: Pavord, Ian D, et al.
Publicado: (2021)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
por: Ghassemian, Arian, et al.
Publicado: (2021)

Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
por: Mukherjee, Manali, et al.
Publicado: (2017)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
por: Pelaia, Corrado, et al.
Publicado: (2017)

Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities
por: Crimi, Claudia, et al.
Publicado: (2020)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2021)

Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET
por: Liu, Mark C., et al.
Publicado: (2022)

Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
por: Liu, Mark C., et al.
Publicado: (2021)

Experience with mepolizumab in adults with severe eosinophilic asthma: a case series from India
por: Maturu, Venkata Nagarjuna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dq3bq4tfekk70noucnmebhu5lm